. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Clin Lab Med. 2017 Sep;37(3):527–546. doi: 10.1016/j.cll.2017.06.006

Table 3.

TNM staging as per ISCL/EORTC revision for mycosis fungoides/Sezary syndrome[55]

Clinical stage	T	N	M	B
IA	1	0	0	0,1
IB	2	0	0	0,1
IIA	1–2	1,2	0	0,1
IIB	3	0–2	0	0,1
IIIA	4	0–2	0	0
IIIB	4	0–2	0	1
IVA1	1–4	0–2	0	2
IVA2	1–4	3	0	0–2
IVB	1–4	0–3	1	0–2

TNM tumor node metastasis, ISCL international society for cutaneous lymphoma; EORTC European organization for the treatment of cancer.

From Olsen, E., et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007. 110(6): p. 1713–22; with permission.